The HSP90 (heat-shock protein 90) inhibitor 17-AAG (17-allylamino-demethoxygeldanamycin) increases osteoclast formation both in vitro and in vivo, an action that can enhance cancer invasion and growth in the bone microenvironment. The cellular mechanisms through which 17-AAG exerts this action are not understood. Thus we sought to clarify the actions of 17-AAG on osteoclasts and determine whether other HSP90 inhibitors had similar properties. We determined that 17-AAG and the structurally unrelated HSP90 inhibitors CCT018159 and NVP-AUY922 dose-dependently increased RANKL [receptor activator of NF-κB (nuclear factor κB) ligand]-stimulated osteoclastogenesis in mouse bone marrow and pre-osteoclastic RAW264.7 cell cultures. Moreover, 17-AAG also enhanced RANKL-and TNF (tumour necrosis factor)-elicited osteoclastogenesis, but did not affect RANKLinduced osteoclast survival, suggesting that only differentiation mechanisms are targeted. 17-AAG affected the later stages of progenitor maturation (after 3 days of incubation), whereas the osteoclast formation enhancer TGFβ (transforming growth factor β) acted prior to this, suggesting different mechanisms of action. In studies of RANKL-elicited intracellular signalling, 17-AAG treatment did not increase c-Fos or NFAT (nuclear factor of activated T-cells) c1 protein levels nor did 17-AAG increase activity in luciferase-based NF-κB-and NFAT-response assays. In contrast, 17-AAG treatment (and RANKL treatment) increased both MITF (microphthalmia-associated transcription factor) protein levels and MITF-dependent vATPase-d2 (V-type proton ATPase subunit d2) gene promoter activity. These results indicate that HSP90 inhibitors enhance osteoclast differentiation in an NFATc1-independent manner that involves elevated MITF levels and activity.
INTRODUCTION
The osteoclast is a multinucleated macrophage-related cell that has a central role in bone metabolism through its ability to directly resorb bone [1] . In bone remodelling and repair, bone resorbed by osteoclasts is replaced by new bone formed by mesenchymally derived osteoblasts [2] , the balance between these two cellular actions maintains bone mass, structure and mechanical qualities. However, this balance can be perturbed by pathological stimuli that increase osteoclast numbers to cause a net loss of bone. This is commonly seen in inflammation and with the invasion of the bone by metastasizing cancer cells, notably breast cancer cells, that cause hypercalcaemia and pathological fractures at the affected sites [2] [3] [4] [5] ; such osteolysis releases bone matrixassociated factors that considerably enhance tumour growth within the bone. The mechanisms that underlie pathological bone loss are not well understood, but are of major clinical interest.
Osteoclast formation from macrophage lineage progenitors is a major point of control in bone resorption and is normally driven by RANKL {RANK [receptor activator of NF-κB (nuclear factor κB)] ligand} and M-CSF (macrophage colony-stimulating factor), the latter a macrophage proliferation and survival factor [1, 6] . RANKL, a member of the TNF (tumour necrosis factor) family, binds its cognate receptor RANK on progenitor cells to elicit signals essential for osteoclastic gene expression [7, 8] . RANKL and its receptor are essential for osteoclast formation in vivo and mice lacking RANK or RANKL are devoid of osteoclasts [9] , although in some circumstances TNF has a low capacity to elicit osteoclast formation [10, 11] . Osteoclast formation is normally regulated by RANKL expression levels in osteoblasts and osteocytes, which is in turn regulated by osteolytic hormones [12] . However, a few local factors can directly act on osteoclast progenitors to enhance RANKL-dependent osteoclastogenesis, notably TGFβ (transforming growth factor β) [13, 14] .
HSP (heat-shock protein) 90 is a ubiquitously expressed ATPase-dependent molecular chaperone that mediates the conformational maturation and stability of its client proteins [15] , including many that participate in cell signalling pathways. These include numerous protein kinases, steroid receptors and transcription factors, some critical for cancer cell growth, survival and progression [16] . Owing to the importance of HSP90 to cancer cells, HSP90 has emerged as a significant therapeutic target in cancer. As a result, a number of HSP90
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inhibitors have been generated, primarily targeting the N-terminal ATPase domain of the molecule. Most of these agents can be grouped according to their structural similarity to the compounds GM (geldanamycin) and RD (radicicol) [17] . These include, respectively, the benzoquinone ansamycin 17-AAG (17-allyl-17-demethoxygeldanamycin) and the resorcinol isoxazole derivative NVP-AUY922. Although 17-AAG potently inhibits soft tissue tumour growth in numerous models [18, 19] and HSP90 inhibition can perturb the signalling molecules involved in osteoclast formation [20] [21] [22] , we found that 17-AAG can still strongly enhance RANKLdriven osteoclast formation in vitro and in vivo, causing significant bone loss [23] . This was consistent with our observation that 17-AAG, surprisingly, increased breast cancer bone metastasis, but not soft tissue tumour growth or invasion in xenograft mouse models [23] . Yano et al. [24] subsequently made similar findings in a prostate cancer xenograft model which further confirmed the importance of osteoclasts in the deleterious effect of 17-AAG on bone. Although the latter study suggested a mediating action for Src kinase, the lack of a fundamental role for Src in osteoclast differentiation suggests other mechanisms exist. The strong enhancement of RANKL-dependent osteoclast formation by 17-AAG raises the possibility that 17-AAG actions are mediated by intracellular signals and/or transcription factors which are induced by RANKL. These include NF-κB, NFATc1 (nuclear factor of activated T-cells, cytoplasmic 1), AP-1 (activator protein 1; a c-Fos/c-Jun dimer) and MITF (microphthalmia-associated transcription factor); when these factors are blocked or absent osteoclast formation does not occur [1] . NFATc1 in particular is considered a critical regulator of osteoclastogenesis as its forced overexpression causes RANKL-independent osteoclast formation [25] . Many osteoclast inhibitory factors can reduce NFATc1 levels, whereas other factors, such as TGFβ, can enhance them [25, 26] . Activated NFATc1 forms complexes that can include transcription factors PU.1, AP-1, NF-κB and MITF [3, 25] and these drive the expression of numerous osteoclast-associated genes.
In the present study we sought to identify critical mechanisms of action of 17-AAG by examining the kinetics of its influence on osteoclast formation and its effects on RANKL-elicited cell signals. Moreover, we also investigated whether other structurally unrelated HSP90 inhibitors with emerging therapeutic potential, namely CCT018159 and NVP-AUY922, similarly influence osteoclast formation. The results of the present study confirm that the those HSP90 inhibitors do indeed potently increase osteoclast formation. Additionally, our extended analysis of 17-AAG demonstrates surprisingly that although no effects on NFATc1, c-Fos or NF-κB were observed, 17-AAG significantly enhances MITF levels and activity. This influence on MITF may thus constitute a novel NFATc1-independent mechanism driving bone loss associated with HSP90 inhibitor treatment, and so may potentially contribute to other types of pathological osteolysis.
MATERIALS AND METHODS

Reagents
17-AAG was purchased from LC Labs, CCT018159 was from Cayman Chemical and NVP-AUY922 purchased from Biovision. L-cell conditioned medium (an impure source of secreted murine M-CSF) was prepared as described in Yeung et al. [27] . For TRAP (tartrate-resistant acid phosphatase) staining, fast Red Violet LB Salt F-1625, naphthol AS-MX phosphate and dimethylformamide were purchased from Sigma-Aldrich. Recombinant soluble murine RANKL was purchased from Oriental Yeast Company, and human M-CSF and TGFβ (TGFβ1 isoform) from R&D Systems.
Antibodies and Animals
Purified anti-CTR (calcitonin receptor) antibody was produced in-house following the method of Tikellis et al. [28] . Mouse monoclonal anti-MITF antibody (C5; ab12039) was purchased from Abcam, and anti-NFATc1 (7A6; sc-7294) and anti-MITF (N15; sc-10999) antibodies were purchased from Santa Cruz Biotechnology. Anti-β-actin clone AC-15 which was used as a loading control for immunoblotting was purchased from Sigma-Aldrich. HRP ( 
Cell cultures
Primary bone marrow macrophage cultures were maintained in L-cell conditioned medium to induce macrophage proliferation as described previously [29] . RAW264.7 cells (A.T.C.C.) and primary bone marrow cells undergoing osteoclast differentiation were cultured in MEM (α-minimal essential medium; Life Technologies) supplemented with 10 % FBS (fetal bovine serum; CSL Biosciences) and containing 0.005 % penicillin (10 000 units/ml)/streptomycin (10 000 units/ml) (Life Technologies), L-glutamine (29.95 mg/ml; Life Technologies) and Hepes (Sigma-Aldrich). Cells were maintained in a 37
• C incubator in a humidified atmosphere containing 5 % CO 2 .
Assays of osteoclast progenitor differentiation, proliferation and activity
Assays for osteoclast formation were performed as described previously [23, 29] with all experiments being performed in quadruplicate wells for each independent experiment. Briefly, RAW264.7 cells (10 4 cells/well) or mouse bone marrow cells (10 5 cells/well) were cultured in 6-mm diameter tissue culture wells containing 0.2 ml of medium (MEM/FBS) with the mouse bone marrow cells being supplemented with 30 ng/ml M-CSF. To induce osteoclast differentiation, the indicated concentrations of RANKL or TNF were added to the cells and replaced after day 3 of culture. On day 6 of incubation, cells were fixed in 4 % buffered formalin for 10 min then washed in methanol/acetone (1:1 ratio), air-dried and histochemically stained for TRAP [30] ; TRAP + cells with >2 nuclei by light microscopy were counted as MNCs (multinucleated cells) or osteoclasts. Some osteoclast-forming cultures were performed on glass coverslips to allow immunohistochemical detection of CTR. On day 6 these cultures were washed, acetone-fixed, dried and immunoperoxidase-stained with 5 μg/ml purified anti-CTR antibody and haematoxylin counterstained as described previously [30] ; as an immunostaining control the anti-CTR antibody was neutralized via incubation with 100 μg/ml antigen (CTR peptide) prior to use [30] . For osteoclast survival assays, osteoclasts were first generated by stimulation of bone marrow cells (5×10 6 cells) in 10-cm diameter tissue culture dishes for 6 days with 100 ng/ml RANKL and 30 ng/ml M-CSF. Cells were then dispersed using non-enzymic cell dispersion buffer (catalogue number C5914, Sigma), rinsed in PBS, resuspended in MEM/10 % FBS and plated at 10 5 cells/well in 6-mm culture wells. Cells were cultured for 24 h with survival factor (RANKL) in conjunction with other treatments. Cells were then fixed and histochemically stained for TRAP and the osteoclast numbers counted; results are expressed relative to the positive control cultures stimulated by 100 ng/ml RANKL alone. For cell proliferation assays RAW264.7 cells were seeded at 10 4 cells per 6-mm diameter culture well and treated with HSP90 inhibitors. Cells were fixed in 4 % formaldehyde and Crystal Violet stained after 1, 3 and 7 days of incubation then dried and eluted before the absorbance at 560 nm was measured on a Wallac EnVision multilabel plate reader (PerkinElmer).
Immunoblot analysis
Immunoblot analysis was performed as described previously [23] . Briefly, cell lysates were generated using modified RIPA buffer [50 mmol/l Tris/HCl (pH 7.4), 1 % Nonidet P40, 0.25 % sodium deoxycholate and 150 mmol/l NaCl] containing protease and phosphatase inhibitors. Protein concentrations were determined by the BCA (bicinchoninic acid) protein assay as per manufacturer's protocol (Pierce). Cell lysates were run on 4-12 % Bis-Tris gradient SDS/PAGE with Mes SDS running buffer (Life Technologies) under reducing conditions and transferred on to PVDF membranes (Roche). Membranes were blocked for 1 h with 3 % dried skimmed milk (Diploma, Fonterra Food services) in PBST (PBS and 0.1 % Tween 20) and incubated overnight at 4
• C with the appropriate primary antibodies. Immunoblot visualization was achieved by incubation with appropriate HRP-conjugated secondary antibodies and the use of an ECL (enhanced chemiluminescence) detection system according to the manufacturer's instructions (Pierce).
Luciferase reporter assays
RAW264.7 cells that had been stably transfected with a construct expressing firefly luciferase driven by a promoter containing either an NF-κB-or an NFAT-response element-containing promoter were used in luciferase reporter assays as described previously [31] . Briefly, reporter cells were seeded at 4×10 4 cells/6-mm diameter culture well in MEM/FBS and incubated overnight. Treatments were performed in triplicate over 24 h, PBS rinsed then lysed with Passive Lysis buffer (Promega) for 24 h at 4
• C. Lysates were transferred to a white flat bottomed 96-well microplate (Corning) and signal was measured using firefly luciferase substrate (Promega) as per manufacturer's instructions using a EnVision multilabel plate reader. Transient transfection of RAW264.7 cells (6×10 4 cells/well) with the vATPase-d2 (Vtype proton ATPase subunit d2) promoter [32] and the M(M1-3)vATPase-d2 promoter (containing mutations in the three MITFbinding sites rendering them non-functional [32] ) was carried out using Lipofectamine TM LTX Plus reagent (Life Technologies) according to the manufacturer's instructions. The vATPase-d2 promoter-luciferase construct (0.2 μg/well) was co-transfected with pRL Renilla luciferase construct (0.1 μg/well; Promega) and after 24 h, cells were rinsed and stimuli applied (in 200 μl of MEM/FBS) for a further 24 h, after which time cells were lysed as above and levels of luciferase determined using luciferase substrate and Stop and Glo ® reagent (Promega) according to the manufacturer's instructions, and light emission was measured using the EnVision plate reader.
Statistical analysis
Data were analysed using Graphpad Prism 5 software, and statistical significance determined using Student's unpaired t test for pair-wise comparisons and ANOVA/Dunnett's post-hoc test (as indicated) for multiple comparisons.
RESULTS
Characterization of the effects of 17-AAG on osteoclast formation in vitro
To characterize the effects of 17-AAG upon osteoclast formation, we employed both M-CSF-stimulated mouse bone marrow cells and the macrophage/pre-osteoclast cell line RAW264.7. Cultures treated with 100 ng/ml RANKL for 6 days, as described previously [23, 31] Figures 1A-1C ). 17-AAG dose-dependently increased TRAP + MNC numbers over 25-100 nM, the latter concentration increasing formation over 3-fold ( Figure 1A ). MNCs in these cultures also expressed CTR, confirming their osteoclast identity [30] (Figure 1D ). At concentrations of 200 nM and above, high cell toxicity with reduced cell survival was observed; similar toxicity was seen in M-CSF-dependent bone marrow-derived macrophages (results not shown). RANKL concentrations were also titrated in the presence of 100 nM 17-AAG or vehicle control ( Figure 1B) , which showed that 17-AAG did not increase osteoclast formation in the absence of RANKL or in the presence of 5 or 10 ng/ml RANKL, but enhancement of TRAP + MNC formation was seen with 20, 50 and 100 ng/ml RANKL treatments ( Figure 1B) . The 50 and 100 ng/ml RANKL treatments resulted in very large MNCs being formed, and in those treated with 17-AAG MNCs with a high number of nuclei were noted. This increased cell fusion was not necessarily reflected in a concomitant increase in total MNC numbers, presumably since fusion between existing MNCs may actually serve to decrease the overall numbers. 17-AAG also enhanced TRAP + MNC formation in RAW264.7 cells treated with 20 ng/ml RANKL, although these cells tolerated up to 200 nM 17-AAG ( Figure 1E ).
Since TNF can also weakly drive osteoclast formation in vitro we investigated whether 17-AAG could also influence its action. In M-CSF-treated bone marrow cells, TNF caused formation of very low numbers of TRAP + MNCs compared with RANKL (less than 3 TRAP + MNCs per well), but this was greatly enhanced by 17-AAG treatment ( Figure 1F ), indicating that 17-AAG enhances osteoclastogenic stimuli, not merely RANK signals. 17-AAG also increased TRAP + cell formation in TNF-treated RAW264.7 cells (results not shown).
To determine whether 17-AAG influences other actions of RANKL, we examined the effect of 17-AAG on the osteoclast prosurvival effects of RANKL. In dispersed osteoclast-rich cultures generated from bone marrow cells there was no cell survival observed in the absence of any RANKL treatment after 24 h of incubation ( Figure 1G ), whereas 100 ng/ml RANKL stimulus (in the absence of M-CSF) resulted in large numbers of TRAP MNCs surviving after 24 h; 20 ng/ml RANKL resulted in lower survival levels than 100 ng/ml. Co-treatment of the cells with 17-AAG (100 nM) was found to have no effect on the osteoclast survival effects of RANKL at any of these concentrations ( Figure 1G ).
Enhancement of osteoclast formation by CCT018159, NVP-AUY922 and TGFβ
As CCT018159 and NVP-AUY922 strongly inhibit HSP90 by binding to the N-terminal ATPase domain of the molecule, yet are structurally distinct from 17-AAG, we studied their influence on osteoclast formation. NVP-AUY922 treatment up to a 10 nM concentration dose-dependently increased TRAP + MNC formation in both bone marrow and RAW264.7 cell cultures (Figures 2A and 2B ), beyond which cell toxicity was observed. Similarly, increased osteoclast formation was observed with CCT018159 treatment (Figures 2C-2E) . As with 17-AAG, increased osteoclast numbers with CCT018159 treatment were seen in cultures maximally stimulated with RANKL (100 ng/ml; Figures 1B and 2F) .
TGFβ strongly enhances RANKL (and TNF) stimulation of osteoclast formation [14] in a manner that resembles 17-AAG. Since we previously found that TGFβ acts in the earlier phases of osteoclast formation we investigated the time course of 17-AAG action on bone marrow cell-osteoclast differentiation. until day 4 of the incubation period ( Figure 3A) , indicating that the early commitment phase of osteoclast formation lasts for at least 3 days in this culture system. TGFβ enhanced TRAP + MNC formation when added during days 0-3, but not days 3-6 of these cultures ( Figure 3B ). In contrast, 17-AAG actions were significant only when added at day 3. This suggests that 17-AAG probably exerts its actions on osteoclast formation through a mechanism significantly different to that of TGFβ.
17-AAG does not stimulate levels of key osteoclast transcription factors NF-κB, NFATc1 and the AP-1 subunit c-Fos
To investigate potential mechanisms of 17-AAG in osteoclast formation, we investigated its actions on transcription factors known to be elicited by RANKL, namely NF-κB, cFos and NFATc1 using immunoblotting and transcriptional luciferase reporter assays that employed RAW264.7 cells. In RAW264.7 cells stably transfected with an NF-κB-luciferase reporter construct [31] 17-AAG did not affect NF-κB signals either directly or with co-stimulation by 100 ng/ml RANKL ( Figure 4A ). Immunoblot analysis also demonstrated that RANKL treatment increased the levels of NFATc1 in a timeand dose-dependent manner, whereas 17-AAG had no effect ( Figures 4B and 4C) . As with NFATc1, a strong increase in c-Fos levels by RANKL was observed, but no effect of 17-AAG was seen ( Figures 4B and 4C) . Consistent with the lack of effect of 17-AAG on NFATc1 protein levels, a luciferase-based activity assay indicated a similar lack of effect on NFATc1 activity ( Figure 4D ). This assay employed RAW264.7 cells stably transfected with an NFAT-dependent luciferase reporter construct (with promoterbinding sites for NFATc1) and both RANKL and TGFβ treatments strongly induced the luciferase signal as described previously [31] , whereas 17-AAG did not ( Figure 4D ). 17-AAG also did not enhance RANKL-induced activity in this assay. These data suggest that NF-κB, NFATc1 and c-Fos, although regulated by numerous factors that influence osteoclast formation, are not the probable mediators of 17-AAG action in osteoclast formation.
17-AAG enhances MITF protein levels and the promoter activity of the MITF target vATPase-d2
MITF is an essential osteoclast transcription factor whose activation has been shown to be dependent on NF-κB, AP-1 and NFATc1 and thus its effects are probably exerted relatively late within the RANKL-dependent transcription factor cascade. In concordance with Lu et al. [8] , we found that RANKL treatment of RAW264.7 cells increased MITF protein expression levels ( Figures 5A and 5B) ; note that a number of MITF isoforms have been described although all bands detected by immunoblotting appeared to be raised by RANKL treatment. We also found that 17-AAG increased MITF levels in RAW264.7 cells in a dose-and time-dependent manner ( Figures 5A and 5B ) with very strong enhancement of MITF protein levels at 48 h. This suggests that MITF could be a mediator of the actions of 17-AAG upon osteoclast formation. To further investigate the action of 17-AAG on MITF, we employed a luciferase reporter construct containing the promoter region of a MITF target gene, vATPased2 ( Figure 5C ). In RAW264.7 cells transiently transfected with this construct RANKL treatment significantly increased the activity of this promoter as reported previously ( Figure 5D ) [32] . Moreover, like RANKL, 17-AAG caused a dose-dependent increase in the activity of the reporter construct ( Figure 5E ). This indicates activation of the MITF target gene vATPase-d2 by both RANKL and 17-AAG. As a further control, we employed a similar construct [M(M1-3)vATPase-d2] containing mutations in all three MITF-binding sites ( Figure 5C ) which render the construct unresponsive to MITF, as described previously [32] . 17-AAG failed to induce a response in RAW264.7 cells transfected with this mutant construct ( Figure 5F , left-hand panel). As a method control, the latter experiments were carried out alongside the same RAW264.7 cells transfected with the wild-type vATPase-d2 construct which did respond to 17-AAG ( Figure 5F , right-hand panel) as before. In conclusion, these results point to an action of 17-AAG in osteoclast formation via its ability to regulate MITF protein expression levels and its activity.
DISCUSSION
We and others have previously identified that benzoquinone ansamycin HSP90 inhibitors, such as 17-AAG and herbimycin, enhance osteoclast formation in vitro and in vivo [23, 24] . These were surprising observations given that HSP90 is an important molecular chaperone that maintains the activity and stability of many important cell signalling proteins [18, 19] . To clarify this action of 17-AAG we first investigated whether enhancing osteoclast formation is a unique feature of the GM class of HSP90 inhibitors to which it belongs. High-throughput biochemical screening originally identified CCT08159 as a high-affinity resorcinol-containing HSP90 ATPase inhibitor that reduced HCT116 human colon cell proliferation [18, [33] [34] [35] and further structure-based rational drug-based design identified NVP-AUY922. The latter is currently undergoing Phase II clinical trials in HER2 + (human epidermal growth factor receptor 2) ERα + (oestrogen receptor α) locally advanced or metastatic breast cancer [19] . CCT018159 and NVP-AUY922 have better pharmacokinetic profiles than 17-AAG and are more likely to provide clinical benefit [36] ; we found both HSP90 inhibitors (compounds structurally dissimilar from those of the GM class) also greatly increased osteoclast numbers in vitro. This suggests that pro-osteoclastic effects are not limited to GM-based HSP90 inhibitors. This may also suggest that such compounds, like 17-AAG, might also provoke bone loss in vivo. Nevertheless, they are anti-cancer compounds with some promise [15, 18] , and if bone loss emerges as a clinical problem it is likely to be overcome by the appropriate use of anti-osteolytic therapies such as bisphosphonates. However, this issue may be more acute in cancers that metastasize to bone, such as breast carcinomas, where osteolysis mediated by osteoclasts is provoked by the invading cancer cells and results in the release of factors from the bone matrix that potently stimulate tumour growth [37] . Consistent with this, a low calcium diet in mice increases bone resorption that in turn increases tumour invasion and growth in bone [38] . In addition, bone metastasis establishment not only results in focal bone damage and other serious complications, but can also result in tumours more refractory to treatment [39] . For these reasons it seems desirable that potential anti-cancer therapeutics such as these should be screened for effects on bone metabolism.
The results of the present study have provided new and surprising insights into the effects of HSP90 inhibitors upon osteoclast progenitors, namely that 17-AAG does not influence their levels of c-Fos (an AP-1 subunit), NF-κB or NFATc1, but does increase the levels of MITF. These are transcription factors critical for osteoclast formation and induced by RANKL, and NFATc1 in particular is regarded as a highly regulated and critical determinant of osteoclast formation [1] . There are thus several ways in which 17-AAG might increase osteoclast formation. HSP90 inhibition results in the proteosomal degradation of many HSP90 client proteins [40] , raising the possibility of the degradation of some intracellular osteoclast inhibitor, perhaps one that reduces MITF levels. It is notable that removal of RANKL-and TNF-inducible endogenous osteoclast inhibitors [NF-κBp100 and RBP-Jκ (recombination signal-binding protein 1 for Jκ) respectively] has been proposed by Zhao et al. [41] and Yao et al. [11] to explain increased osteoclast formation in their models. These factors, however, also result in greatly enhanced NFATc1 levels, which we do not observe with 17-AAG treatment. A more likely possibility is suggested by the observations that many HSP90 inhibitors cause a dissociation of the HSP90 complex with HSF1 (heat-shock factor 1) leading to HSF1 activation and the initiation of an HSF1-mediated cell stress response [42] characterized by increased levels of HSPs such as HSP70. This raises the possibility that the increased MITF levels observed upon 17-AAG treatment may be cell-stress-dependent. Indeed, MITF levels have been shown to be induced in epithelial cells upon heat shock and consistent with this the MITF gene promoter is known to contain a number of HSF1-binding motifs [43] . 17 for pro-osteoclastic effects of 17-AAG is via MAPK (mitogenactivated protein kinase) signalling proteins. HSP90 inhibition can lead to increased p38 activation [44] and p38 activity is critical in osteoclast differentiation [1] . It should be noted, however, that the effect of 17-AAG on MAPK proteins varies between cell types [21] and has not yet been examined in osteoclast progenitors. In addition, since p38 inhibition completely blocks osteoclast formation its role in this process is not easy to determine.
Further characterization of the 17-AAG pro-osteoclastic action (confirmed by detection of CTR expression in the MNCs) showed that this action clearly required a minimal RANKL stimulus of the osteoclast progenitors; in the present study this was a >10 ng/ml RANKL stimulus, a level that barely elicits detectable TRAP + cell formation ( Figure 1B ). 17-AAG also caused supramaximal increases in RANKL-stimulated osteoclast formation. These data are consistent with an action of 17-AAG to enhance differentiation mechanisms somewhere downstream of RANK binding, i.e. it did not simply raise the general sensitivity of cells to RANKL. The lack of effects of 17-AAG on RANKL-dependent osteoclast survival also suggests this conclusion, as does the huge effect of 17-AAG on osteoclast formation driven by TNF ( Figures 1F  and 1G ). TNF does not bind the RANKL receptor (RANK), but acts via the TNFR (TNF receptor) p55 and p75 receptors to elicit the activation of NF-κB and a number of downstream mediators, the same as RANKL treatment does. The results of the present study also raise the possibility that HSP90 inhibitors may enhance TNF-driven osteolysis, although the influence of TNF, especially in vivo, is complex. High TNF levels are associated with osteolysis in vivo, often in the context of chronic inflammation, but . (E and F) *P < 0.05, **P < 0.01 and ***P < 0.001 relative to the control using ANOVA/Bonferroni's post-hoc test (n = 5).
TNF also induces RANKL protein expression in osteoblasts and suppresses bone formation. In vitro TNF-dependent osteoclast formation is well attested, but is not observed in RANK-null mice in vivo, suggesting that TNF-driven osteoclast formation in vivo is totally RANKL dependent. This lack of direct action of TNF was explained by two studies that identified osteoclastsuppressive intracellular pathways involving NF-κBp100 and RBP-Jκ (see above) which are induced by TNF [11, 41] ; disabling these mechanisms by genetic manipulation resulted in direct TNF-driven osteoclast formation in RANK-null mice in vivo. Although mechanistically interesting it is not yet clear if these molecules play a role in TNF-induced bone loss in human disease or inflammatory models of wild-type mice, so it is currently unclear whether the effect of 17-AAG on bone might include TNF-mediated actions.
Since TGFβ is one of the few exogenous factors that can enhance osteoclast formation by direct action on progenitors, we compared its influence to that of 17-AAG. TGFβ can prime osteoclast progenitors to respond to RANKL [45] . As observed previously [26, 46] we found that, like RANKL, TGFβ enhanced NFATc1 levels, consistent with the effects of TGFβ being mainly evident in the earlier period of the bone marrow culture period (Figure 3) . In contrast, 17-AAG exerted its influence later than this, suggesting that the mechanism of actions of TGFβ and 17-AAG differ substantially.
The lack of effects of 17-AAG on NFATc1 levels played a major role in our decision to focus on MITF as a possible mediating transcription factor. It should be noted that we examined the total cellular levels of NFATc1 (i.e. in unfractionated cell lysates) since this typically reflects the levels of NFATc1 in the nucleus and is a widely adopted approach. As a transcription factor, NFATc1 requires nuclear translocation to act, indeed NFATc1 binds to the promoter of its own gene further accelerating its own transcription and production [46] . However, to date, the nuclear transport of NFATc1 has not been determined to be a point of control in osteoclast differentiation. To definitively identify any effects of 17-AAG on NFATc1 activity we used an NFAT-luciferase reporter assay in RAW264.7 cells. Consistent with our findings of a lack of an effect of 17-AAG upon NFATc1 protein levels, 17-AAG (unlike TGFβ) had no effect on NFATc1 activity. However, MITF activation is downstream of NFATc1 and occurs later in the osteoclast signalling/transcription factor cascade. MITF is a widely expressed basic helix-loop-leucine zipper transcription factor required for the latter stages of osteoclastogenesis [3, 47] . MITF binds to a conserved 7 bp motif, TCANGTG, in the promoter region of target genes, which include vATPase-d2 subunit, TRAP [Acp5 (acid phosphatase 5, tartrate resistant)], Ctsk (cathespin K) and E-cadherin [3, 32, 48] . MITF participates in the transcription factor complexes needed for osteoclast gene expression, complexes which include NFATc1, PU.1, NF-κB and AP-1. Mice that express mutant alleles of the MITF gene, mi, have few and defective osteoclasts [48] and mice null for MITF display osteopetrosis and lack osteoclasts. The MITF gene transcript is alternatively spliced and exists in at least 8 isoforms, and when isoforms A and E are overexpressed osteoclast formation is enhanced [8] . MITF protein levels induction may thus plausibly explain, at least in part, the actions of 17-AAG in osteoclast formation. Given that 17-AAG does not enhance NFATc1 and other important upstream targets of RANKL, MITF levels might be rate limiting for osteoclast formation. Although the importance of MITF in osteoclasts has been long recognized, it is not generally considered as a point of regulation, although Kim et al. [49] have suggested that IL-1 (interleukin 1) regulation of MITF activity might enhance osteoclast formation when IL-1 is added late in the osteoclast maturation period. This latter observation seems similar to our observations with 17-AAG (Figure 3) .
Thus, in summary, HSP90 inhibitors have a powerful stimulatory effect on osteoclast formation in vitro which is consistent with previously observed osteolytic actions of 17-AAG in mice [23, 24] . 17-AAG, even in the absence of RANKL, increases the levels of MITF in osteoclast progenitors, an essential transcription factor in osteoclast formation. This may underlie the osteoclastic effects of HSP90 inhibitors. If that is the case it seems
